
Opinion|Videos|July 24, 2024
Long-Term Follow-Up from CheckMate 9LA at ASCO 2024
Author(s)Jason Porter, MD
A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.
Advertisement
Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on overall survival from the
CheckMate 9LA study with the use of nivolumab + ipilimumab + chemotherapy in patients with metastatic NSCLC. - What are your key takeaways from this study?
- How do you think the long term follow up data supports decision-making in metastatic NSCLC?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5